BridgeBio PharmaBBIO
BBIO
About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Employees: 556
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
317% more call options, than puts
Call options by funds: $288M | Put options by funds: $69M
43% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 72
14% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 35
8% more funds holding in top 10
Funds holding in top 10: 12 [Q2] → 13 (+1) [Q3]
0% more funds holding
Funds holding: 248 [Q2] → 249 (+1) [Q3]
2% less capital invested
Capital invested by funds: $4.47B [Q2] → $4.4B (-$73.8M) [Q3]
2.46% less ownership
Funds ownership: 94.29% [Q2] → 91.83% (-2.46%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
20%
upside
Avg. target
$48
28%
upside
High target
$50
33%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Cory Kasimov 40% 1-year accuracy 6 / 15 met price target | 33%upside $50 | Outperform Maintained | 23 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 134 / 322 met price target | 30%upside $49 | Buy Reiterated | 16 Dec 2024 |
Scotiabank Greg Harrison 45% 1-year accuracy 13 / 29 met price target | 28%upside $48 | Sector Outperform Maintained | 25 Nov 2024 |
B of A Securities Geoff Meacham 41% 1-year accuracy 11 / 27 met price target | 20%upside $45 | Buy Maintained | 25 Nov 2024 |
Financial journalist opinion
Based on 8 articles about BBIO published over the past 30 days
Negative
Benzinga
5 days ago
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Positive
Seeking Alpha
1 week ago
BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Attruby's recent approval positions BBIO as a direct competitor to PFE's Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a superior profile in some cases relative to Vyndaqel. BBIO is now also set to receive $500 million in milestone payments related to Attruby's approval, and I expect they'll get an additional $105 million from EU and Japan approvals.
Positive
CNBC Television
1 week ago
BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
BridgeBio CEO Neil Kumar joins CNBC's 'Power Lunch' to discuss the company's latest drug developments, how the drugs compares to competitors in the space, and more.
Positive
Zacks Investment Research
1 week ago
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Investors Business Daily
1 week ago
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Neutral
GlobeNewsWire
1 week ago
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types
Positive
CNBC
2 weeks ago
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Neutral
GlobeNewsWire
2 weeks ago
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.
Neutral
GlobeNewsWire
1 month ago
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. In the Phase 3 study ATTRibute-CM, acoramidis showed clear benefits on cardiovascular outcomes.
Neutral
GlobeNewsWire
1 month ago
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (Nasdaq: BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
Charts implemented using Lightweight Charts™